Horn Howard
Horn Howard, CFO, reported an open-market or private sale at Ultragenyx Pharmaceutical Inc. involving 7066.000000 shares for an estimated $107897.82. Reported holdings after the transaction were 89229.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Oct 15, 2026
- Filing date
- Oct 19, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 96,295 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
RARE price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001193125-26-425032 Common Stock
- Transaction date
- Oct 15, 2026 Filed Oct 19, 2026, 05:48 PM · 4d delay
- Shares
- 7,066 sh $15.27 per share
- Estimated value
- -$107k Computed from shares × price
- Holdings after
- 89,229 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
+6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Financial Officer
- F1
Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- F2
Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
0 other transactions
0 recent txs